Tag: Crexont

Over 10 million people worldwide are living with Parkinson's disease, a progressive neurological disorder. Managing symptoms has seen significant advancement with the question, **what is the new drug for Parkinson's disease?**, leading to recent FDA approvals for more advanced treatment options, including new infusion pumps and extended-release medications.

In August 2024, the FDA approved Crexont® (carbidopa and levodopa) extended-release capsules, marking a significant advancement in Parkinson's disease treatment. This innovation directly addresses motor fluctuations in patients, offering a longer-lasting effect than many existing oral formulations. Here we answer **what is the new drug for carbidopa-levodopa** and explore how this novel therapy is impacting care.

Parkinson's disease is the world's fastest-growing neurological disorder, with projections suggesting over 25 million people could be affected by 2050 [1.6.1, 1.6.3]. This escalating health challenge drives a pressing search for better treatments. So, what is the new pill for Parkinson's disease? Several promising options have recently emerged.